340 TGFβDNRII genetically-engineered TIL: characterizing final drug product from a phase I clinical trial

• Yue Li,
• Chantale Bernatchez,
• Rodabe Amaria,
• Marie-Andree Forget,
• Priya Balasubramanian,
• Katrina Adlerz,
• Ellgar Jafari,
• Jane Zulovich,
• Donald Sakellariou-Thompson,
• Jason Bock

Affiliations

Yue Li

1Cell Therapy Manufacturing Center (CTMC), Houston, TX, USA

Chantale Bernatchez

Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Rodabe Amaria

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Marie-Andree Forget

Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Priya Balasubramanian

Ziopharm Oncology, Inc., Boston, MA, USA

Katrina Adlerz

1Cell Therapy Manufacturing Center (CTMC), Houston, TX, USA

Ellgar Jafari

1Cell Therapy Manufacturing Center (CTMC), Houston, TX, USA

Jane Zulovich

1Cell Therapy Manufacturing Center (CTMC), Houston, TX, USA

Donald Sakellariou-Thompson

1Cell Therapy Manufacturing Center (CTMC), Houston, TX, USA

Jason Bock

1Cell Therapy Manufacturing Center (CTMC), Houston, TX, USA